Barclays PLC Purchases 151,458 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Barclays PLC lifted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 177.6% in the third quarter, HoldingsChannel.com reports. The fund owned 236,742 shares of the company’s stock after purchasing an additional 151,458 shares during the period. Barclays PLC’s holdings in Humacyte were worth $1,288,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. nVerses Capital LLC purchased a new position in shares of Humacyte in the second quarter worth approximately $28,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte in the third quarter worth about $75,000. Principal Financial Group Inc. bought a new position in shares of Humacyte in the second quarter worth about $83,000. FORA Capital LLC purchased a new position in shares of Humacyte during the 3rd quarter valued at about $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte in the second quarter worth $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is currently owned by insiders.

Humacyte Trading Up 4.0 %

HUMA opened at $5.50 on Friday. The firm has a market cap of $692.22 million, a price-to-earnings ratio of -4.10 and a beta of 1.38. The stock has a fifty day moving average price of $4.77 and a 200-day moving average price of $5.76. Humacyte, Inc. has a 12 month low of $2.48 and a 12 month high of $9.97. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on HUMA shares. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Benchmark raised their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. Finally, BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.